Medical Condition News

RSS

Genetic expression can be modified with natural substances to prevent chronic illness

Research findings demonstrating how genetic expression can be modified with natural substances to prevent chronic illness was the topic of an address by Jeffrey Bland, Ph.D., FACN, FACB, at the 8th Annual Scripps Center for Integrative Medicine 2011 conference in San Diego, California, January 13 - 16.

20 Jan 2011

Cognition Therapeutics closes $2.5 million Series A1 financing

Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.

20 Jan 2011

American Lung Association releases 2010 State of Tobacco Control Report

The American Lung Association released its State of Tobacco Control 2010 report today, which tracks progress on key tobacco control policies at the federal and state level, assigning grades based on whether laws are adequately protecting citizens from the enormous burden caused by tobacco use.

20 Jan 2011

Chelsea reports top-line data from Phase III NORTHERA extension study in NOH

Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.

20 Jan 2011

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

20 Jan 2011

ACD CPR performed with combination of ResQPump and ResQPOD could save lives of cardiac arrest patients

A combination of two devices could save the lives of thousands of cardiac arrest patients each year if implemented nationwide, suggests clinical trial results published in today's online edition of The Lancet.

20 Jan 2011

Neuros Medical announces initial feasibility study results of HFAC Nerve Block technology

Neuros Medical, Inc., a medical device company announced today initial feasibility study results of their patented high frequency alternating current (HFAC) Nerve Block technology from their first patient. The study is a short-term, 30-day test per patient, focusing on chronic residual limb pain. Nearly one million patients suffer from chronic residual limb pain in the U.S.

20 Jan 2011

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

ZIOPHARM Oncology, Inc., announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for darinaparsin (Zinapar™ or ZIO-101) designation as an orphan medicinal product for the treatment of peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Significant portion of U.S. population does not have access to trauma care

A significant portion of the U.S. population does not have access to trauma care within an hours' drive, with certain vulnerable groups at higher risk of worse access, according to a report in the January issue of Archives of Surgery, one of the JAMA/Archives journals.

20 Jan 2011

Damaged alpha-synuclein proteins can spread in a 'prion-like' manner: Study

The study, published in the Journal of Clinical Investigation, reveals that damaged alpha-synuclein proteins can spread in a 'prion-like' manner, an infection model previously described for diseases such as BSE.

20 Jan 2011

HIV-infected patients three times more likely to suffer strokes

While the overall hospitalization rate for stroke has declined in recent years, the numbers have jumped dramatically for patients infected with human immunodeficiency virus (HIV), suggesting they may be up to three times more likely to suffer a stroke than people uninfected by the virus that causes AIDS.

20 Jan 2011

Prevention of awareness during anesthesia

Out of every 1000 patients, two at most wake up during their operation. Unintended awareness in the patient is thus classified as an occasional complication of anesthesia—but being aware of things happening during the operation, and being able to recall them later, can leave a patient with long-term psychological trauma.

20 Jan 2011

Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study

Merck reported today that investigators in the TRA-2P study of vorapaxar have been provided with additional information about the recommendations of the Data and Safety Monitoring Board (DSMB) regarding the TRA-2P study. The additional information was sent yesterday in a communication to investigators from the Operations Committee of the TRA-2P study of vorapaxar. Vorapaxar is one of Merck's investigational cardiovascular medicines.

20 Jan 2011

No robust conclusions possible on advantages or disadvantages of PET

Malignant gliomas are fast-growing brain tumours with poor prospects of recovery depending on disease stage. Experts hope that the examination of patients by means of positron emission tomography (PET) is more helpful in the choice of the right treatment than other procedures. In a final report the German Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated the benefit of PET in the detection of recurrences. According to this report, no robust conclusions are possible on the advantages or disadvantages of PET.

20 Jan 2011

ISCT launches commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease

In keeping with its commitment to connect industry, regulatory experts, therapeutic societies and translational centers to advance emerging cellular therapies, ISCT announces its first commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease (PVD).

20 Jan 2011

Message of health benefits of moderate drinking are hazardous and extremely dangerous

A Letter to the Editor entitled "What should we advise about alcohol consumption?" was recently published by Maurizio Ponz de Leon in Intern Emerg Med.1 Dr. de Leon argues that the message of health benefits of moderate drinking "seems to me hazardous and extremely dangerous to diffuse in the general population."

20 Jan 2011

Scientists discover fundamental mechanism behind toxic protein aggregation in neurodegenerative diseases

Protein aggregation underlies several neurodegenerative diseases such as Alzheimer's, Huntington's chorea or Parkinson's. Scientists at the Max Planck Institute of Biochemistry (MPIB) in Martinsried near Munich, Germany, now discovered a fundamental mechanism which explains how toxic protein aggregation occurs and why it leads to a widespread impairment of essential cellular functions.

20 Jan 2011

Brains of migraine sufferers show higher proportion of lesions of brain microvessels

Recent work, in particular the CAMERA study, has used MRI to study the brains of migraine sufferers and has shown that a higher proportion of these patients exhibit lesions of the brain microvessels than the rest of the population.

20 Jan 2011

Ultrasound device shows promise in breaking up pulmonary embolisms: Research

A tiny ultrasound device that helps dissolve blood clots is showing promise in breaking up potentially deadly pulmonary embolisms, blockages of blood vessels in the lungs that can occur after long plane rides, surgery and extended bed rest.

20 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Medical Condition News

Genetic expression can be modified with natural substances to prevent chronic illness

Cognition Therapeutics closes $2.5 million Series A1 financing

American Lung Association releases 2010 State of Tobacco Control Report

Chelsea reports top-line data from Phase III NORTHERA extension study in NOH

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

ACD CPR performed with combination of ResQPump and ResQPOD could save lives of cardiac arrest patients

Neuros Medical announces initial feasibility study results of HFAC Nerve Block technology

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

Significant portion of U.S. population does not have access to trauma care

Damaged alpha-synuclein proteins can spread in a 'prion-like' manner: Study

HIV-infected patients three times more likely to suffer strokes

Prevention of awareness during anesthesia

Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study

No robust conclusions possible on advantages or disadvantages of PET

ISCT launches commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease

Message of health benefits of moderate drinking are hazardous and extremely dangerous

Scientists discover fundamental mechanism behind toxic protein aggregation in neurodegenerative diseases

Brains of migraine sufferers show higher proportion of lesions of brain microvessels

Ultrasound device shows promise in breaking up pulmonary embolisms: Research

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Latest News